Agitation,Psychomotor Clinical Trial
Official title:
Prospective Observational Investigation of Olanzapine Versus Midazolam for the Treatment of Acute Undifferentiated Agitation in the Emergency Department
The goal of this research investigation is to conduct a prospective observation of the comparative efficacy of midazolam versus olanzapine for the treatment of acute undifferentiated agitation in the emergency department.
The goal of this research investigation is to conduct a prospective observation of the
comparative efficacy of midazolam versus olanzapine for the treatment of acute
undifferentiated agitation in the emergency department.
In the summer of 2017, the ED implemented a treatment protocol as a quality improvement
initiative. The investigators performed observational research on this protocol and
identified that haloperidol and ziprasidone were inferior to midazolam and olanzapine for
treating agitation in our Department.
The comparison between olanzapine and midazolam, however, was inconclusive. It is possible
that this is due to inadequate power, so the question of whether olanzapine or midazolam is
superior is still unknown.
Because the department continues to strive to achieve the best care for this patient
population, in the Summer of 2018 the ED is going to initiate a second ED treatment protocol
of olanzapine and midazolam, based on the results of our 2017 protocol.
All patients requiring chemical sedation for will receive olanzapine as the initial treatment
for agitation for 6 weeks, followed by midazolam as the initial treatment for agitation for 6
weeks. These patients will be observed by research staff.
This is a clinical care quality improvement protocol. The clinical protocol is not research.
The research component is the observation of this clinical care protocol.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT03110900 -
Inhaled Loxapine vs Intramuscular (IM) Haloperidol + Lorazepam for Agitation
|
Phase 4 | |
| Completed |
NCT05272501 -
CAlming Touch for People With Agitation or Other Behavioural Symptoms of DEMentia - A Randomized Feasibility Trial
|
N/A | |
| Completed |
NCT06041646 -
Tachyphylaxis, Tolerance, & Withdrawal Post Treatment With Igalmi for Agitation in Schizophrenia or Bipolar Disorder
|
Phase 4 | |
| Recruiting |
NCT06217146 -
A Medical Cannabis Oil for Treatment of Agitation and Disruptive Behaviors in Subjects With Dementia.
|
N/A | |
| Recruiting |
NCT05543681 -
IGC-AD1 Trial on Agitation in Dementia Due to Alzheimer's
|
Phase 2 | |
| Recruiting |
NCT03513549 -
Observational Study Evaluating the Safety of ADASUVE® in Agitation Associated With Schizophrenia or Bipolar I Disorder
|
||
| Active, not recruiting |
NCT05658510 -
Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III)
|
Phase 3 | |
| Not yet recruiting |
NCT05612711 -
Dronabinol for Agitation in Dementia Crossover Trial
|
Phase 2 | |
| Recruiting |
NCT04957238 -
Physical Restraints in Intensive Care Unit Patients
|
N/A | |
| Completed |
NCT03208452 -
The Effect of Intraoperative Magnesium Sulfate Infusion on the Occurrence of Emergence Agitation
|
Phase 4 | |
| Completed |
NCT03211897 -
Olanzapine, Haloperidol, Ziprasidone, Midazolam for Acute Undifferentiated Agitation
|
N/A | |
| Recruiting |
NCT05783505 -
A Multicomponent Intervention Program to Prevent and Reduce ICU Agitation and Physical Restraint Use
|
N/A | |
| Completed |
NCT04053426 -
Agitation Follow up After Introduction of a New Patient Care Algorithm
|
||
| Completed |
NCT03226522 -
Addressing Dementia Via Agitation-Centered Evaluation
|
Phase 2/Phase 3 | |
| Recruiting |
NCT03926520 -
Electroconvulsive Therapy (ECT) for Agitation in Dementia (AD)
|
N/A | |
| Recruiting |
NCT04075435 -
Cannabidiol Solution for the Treatment of Behavioral Symptoms in Older Adults With Mild Cognitive Impairment or Alzheimer's Dementia
|
Early Phase 1 | |
| Completed |
NCT04276883 -
Dexmedetomidine in the Treatment of Agitation Associated With Bipolar Disorder
|
Phase 3 | |
| Completed |
NCT04797715 -
Assessing Clinical Outcomes in Alzheimer's Disease Agitation
|
Phase 3 | |
| Completed |
NCT04251910 -
Sub-Lingual Dexmedetomidine in Agitation Associated With Dementia
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05765162 -
Safe Brain Initiative, Operationalizing Precision Anaesthesia
|